AGL vs. VRCI, GENI, ABDX, PRM, DXRX, C4XD, AREC, IUG, TRX, and RENX
Should you be buying ANGLE stock or one of its competitors? The main competitors of ANGLE include Verici Dx (VRCI), GENinCode (GENI), Abingdon Health (ABDX), Proteome Sciences (PRM), Diaceutics (DXRX), C4X Discovery (C4XD), Arecor Therapeutics (AREC), Intelligent Ultrasound Group (IUG), Tissue Regenix Group (TRX), and Renalytix (RENX). These companies are all part of the "medical" sector.
Verici Dx (LON:VRCI) and ANGLE (LON:AGL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
ANGLE has a consensus price target of GBX 70, indicating a potential upside of 294.37%. Given Verici Dx's higher possible upside, analysts clearly believe ANGLE is more favorable than Verici Dx.
ANGLE received 181 more outperform votes than Verici Dx when rated by MarketBeat users.
Verici Dx has higher earnings, but lower revenue than ANGLE. ANGLE is trading at a lower price-to-earnings ratio than Verici Dx, indicating that it is currently the more affordable of the two stocks.
In the previous week, ANGLE had 4 more articles in the media than Verici Dx. MarketBeat recorded 4 mentions for ANGLE and 0 mentions for Verici Dx. Verici Dx's average media sentiment score of 0.41 beat ANGLE's score of 0.00 indicating that ANGLE is being referred to more favorably in the news media.
47.4% of Verici Dx shares are owned by institutional investors. Comparatively, 27.2% of ANGLE shares are owned by institutional investors. 17.1% of Verici Dx shares are owned by insiders. Comparatively, 10.7% of ANGLE shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Verici Dx has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, ANGLE has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.
Verici Dx's return on equity of -69.68% beat ANGLE's return on equity.
Summary
ANGLE beats Verici Dx on 8 of the 14 factors compared between the two stocks.
Get ANGLE News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
